	US 12,287,341 B2
	Assays and methods for targeted treatment of hydrosalpinx
Elizabeth H. Yohannes, University Place, WA (US); Avedis A. Kazanjian, Olympia, WA (US); and Richard O. Burney, University Place, WA (US)
Assigned to GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY, Fort Detrick, MD (US)
Filed by GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY, Fort Detrick, MD (US)
Filed on Aug. 2, 2022, as Appl. No. 17/879,330.
Application 17/879,330 is a division of application No. 16/352,683, filed on Mar. 13, 2019, abandoned.
Claims priority of provisional application 62/642,378, filed on Mar. 13, 2018.
Prior Publication US 2023/0176073 A1, Jun. 8, 2023
Int. Cl. G01N 33/68 (2006.01)

CPC G01N 33/6893 (2013.01) [G01N 2333/46 (2013.01); G01N 2333/4704 (2013.01); G01N 2333/90283 (2013.01); G01N 2333/91177 (2013.01); G01N 2800/367 (2013.01)]

2 Claims

1. A method comprising:

detecting, by quantitative ELISA, a presence of mesothelin in a plasma sample from a subject;

identifying the subject as having hydrosalpinx if the sample comprises

an increased level of mesothelin relative to a control, or comprises a level of mesothelin corresponding to a hydrosalpinx control;

and

administering a hydrosalpinx therapy to the subject, wherein the hydrosalpinx therapy comprises sclerotherapy, surgical removal or excision of all or a part of a fallopian tube, fallopian tube dilation, or removal of fallopian adhesion.